SIX Financial Information

Enter Ticker Symbol:

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Actinium Pharmaceuticals, Inc. (ATNM : AMEX)

• Company Description

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. Actinium's lead application for their ARCs is targeted conditioning, which is intended to selectively deplete a patient's disease or cancer cells and certain immune cells prior to a BMT or Bone Marrow Transplant, Gene Therapy or Adoptive Cell Therapy (ACT) such as CAR-T to enable engraftment of these transplanted cells with minimal toxicities. With their ARC approach, they seek to improve patient outcomes and access to these potentially curative treatments by eliminating or reducing the non-targeted chemotherapy that is used for conditioning in standard practice currently. Their lead product candidate, I-131 apamistamab (Iomab-B) is being studied in the ongoing pivotal Phase 3 Study of Iomab-B in Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning. The SI
Number of Employees: 25

• Price / Volume Information

Yesterday's Closing Price: $1.03 Daily Weekly Monthly

20 Day Moving Average: 151,928 shares

Shares Outstanding: 31.44 (millions)

Market Capitalization: $32.38 (millions)

Beta: 0.05

52 Week High: $1.74

52 Week Low: $0.74

Short Interest Ratio:

% Price Change % Price Change Relative to S&P 500

4 Week 33.73% 34.33%

12 Week 3.00% 0.81%

Year To Date -24.26% -32.83%

• Address & Contact Information

Street Address Phone / Fax Email Address Web URL

100 Park Ave. 23rd Floor
-
NEW YORK,NY 10017
USA ph: 646-677-3870
fax: - investorrelations@actiniumpharma.com http://www.actiniumpharma.com

• General Corporate Information

Officers

Sandesh Seth - Chairman and Chief Executive Officer
June Almenoff - Director
Jeffrey Chell - Director
David Nicholson - Director
Richard I. Steinhart - Director

Peer Information

- (-)
- (-)
- (-)
- (-)
- (-)
- (-)

Industry / Sector / Ticker Info

Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 00507W206
SIC: 2834

Fiscal Year

Fiscal Year End: December
Last Reported Quarter: 06/01/26
Next Expected EPS Date: 11/13/26

Share - Related Items

Shares Outstanding: 31.44
Most Recent Split Date: 8.00 (0.03:1)
Beta: 0.05
Market Capitalization: $32.38 (millions)

• EPS Information    • Dividend Information

Analyst Coverage: No Dividend Yield: 0.00%

Current Fiscal Quarter EPS Consensus Estimate: $-0.27 Indicated Annual Dividend: $0.00

Current Fiscal Year EPS Consensus Estimate: $0.12 Payout Ratio: 0.00

Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:

Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00

Next EPS Report Date: 11/13/26

• Fundamental Ratios

P/E

Current FY Estimate: 8.58
Trailing 12 Months: 2.86
PEG Ratio: -

Price Ratios

Price/Book: 1.07
Price/Cash Flow: -
Price / Sales: -

EPS Growth

vs. Year Ago Period: 504.55%
vs. Previous Quarter: 594.44%

Sales Growth

vs. Year Ago Period: -%
vs. Previous Quarter: -%

ROE

06/30/26 - 83.42
03/31/26 - -218.66
12/31/25 - -204.37

ROA

06/30/26 - 23.37
03/31/26 - -43.39
12/31/25 - -56.58

Current Ratio

06/30/26 - 4.08
03/31/26 - 5.89
12/31/25 - 6.20

Quick Ratio

06/30/26 - 4.08
03/31/26 - 5.89
12/31/25 - 6.20

Operating Margin

06/30/26 - -
03/31/26 - -
12/31/25 - -

Net Margin

06/30/26 - -
03/31/26 - -
12/31/25 - -

Pre-Tax Margin

06/30/26 - 32.23
03/31/26 - -26,078.89
12/31/25 - -37,652.22

Book Value

06/30/26 - 0.97
03/31/26 - 0.07
12/31/25 - 0.25

Inventory Turnover

06/30/26 - -
03/31/26 - -
12/31/25 - -

Debt-to-Equity

06/30/26 - 0.00
03/31/26 - 0.00
12/31/25 - 0.00

Debt-to-Capital

06/30/26 - 0.00
03/31/26 - 0.00
12/31/25 - 0.00

Powered by Zacks Investment Research ©